½ÃÀ庸°í¼­
»óǰÄÚµå
1519402

¼¼°èÀÇ ºñPVC IV¹é ½ÃÀå º¸°í¼­ : Àç·áº°, Á¦Ç°º°, ³»¿ë¹°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Non-PVC IV Bags Market Report by Material, Product, Content, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 147 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àü ¼¼°è ºñPVC IV °¡¹æ ½ÃÀå ±Ô¸ð´Â 2023³â 18¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¾ÕÀ¸·Î IMARC GroupÀº 2024-2032³â¿¡ °ÉÃÄ 6.1%ÀÇ ¼ºÀå·ü(CAGR)À» º¸À̸ç, 2032³â¿¡´Â 31¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ºñPVC(ºñÆú¸®¿°È­ºñ´Ò) IV(Á¤¸Æ³» Åõ¿©) ¹éÀº Æú¸®ÇÁ·ÎÇÊ·», Æú¸®¿¡Æ¿·», ÄÚÆú¸®¿¡½ºÅ׸£ ¿¡Å׸£, ¿¡Æ¿·» ºñ´Ò ¾Æ¼¼Å×ÀÌÆ® Çʸ§À» »ç¿ëÇÏ¿© Á¦Á¶µË´Ï´Ù. À̵éÀº ƯÈ÷ º´¿ø ¹× µ¿¹° º´¿ø¿¡¼­ »ç¿ëµÇ´Â º¸¼ö¾× Æ÷Àå ¹× Æ¯Á¤ Ç×»ýÁ¦ ¹× ÁøÅëÁ¦ÀÇ º¸°üÀ» À§ÇØ ¼³°èµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, º¸°üǰÀÇ Ç°ÁúÀ̳ª º¸Á¸ ±â°£À» ÀúÇØÇÏÁö ¾Ê°í Àú¿Â ÀúÀå¿¡ ³Î¸® ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾àÁ¦¿Í ¿ë±âÀÇ »óÈ£ÀÛ¿ëÀÌ ¹®Á¦°¡ µÇ´Â °æ¿ì°¡ ¸¹Àº PVCÁ¦ ¼ö¾×¹é°ú´Â ´Þ¸®, ¾ÈÀü¼ºÀÇ Çâ»ó, ¿À¿° ¸®½ºÅ©ÀÇ Àú°¨, »ç¿ë»óÀÇ Æí¸®¼ºÀÇ Çâ»óÀ» ½ÇÇöÇÕ´Ï´Ù. ±× °á°ú, ºñ¿°ºñ ÁÖÀÔ °¡¹æÀº ºñ°æ±¸ ¿µ¾ç, Á¾¾çÇÐ, È­Çпä¹ý, Ç¥Àû ¾à¹° Àü´Þ µî ±¤¹üÀ§ÇÑ ¿ëµµ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

ºñ PVC Á¦ IV °¡¹æ ½ÃÀå µ¿Çâ :

½ÃÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ´ëÁßµé »çÀÌ¿¡¼­ ¿ø³» °¨¿°(HAI)ÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù. Ç×»ýÁ¦ÀÇ Á¡ÀûÀ» ÇÊ¿ä·Î Çϴ ȯÀÚ°¡ ÀÇ·á ½Ã¼³¿¡ À¯ÀÔÇÏ°Ô µÈ °Íµµ, ºñ¿°ºñÁ¦ ¹æ¿ï ¹éÀÇ º¸±ÞÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °ü¸®, ¿î¼Û, Æó±âÀÇ ÆíÀǼºÀ¸·ÎºÎÅÍ, Á¡ÀûÀ̳ª ±× ¹ÛÀÇ È¥ÇÕ¹°¿¡ 1½Ç À¯ÇüÀÇ ºñ¿°ºñÁ¦ IV¹éÀÌ ³Î¸® ä¿ëµÇ°í ÀÖ´Â °Íµµ, µ¿Á¦Ç°ÀÇ ¸ÅÃâ¿¡ Å©°Ô °øÇåÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¼¼°è¿¡¼­ POC(Point of Care) ½Ã¼³ÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ³ëÀÎÃþ¿¡¼­ ÀçÅà ÄÉ¾î ¼³Á¤ÀÌ ¼±È£µÇ´Â °ÍÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¶ÇÇÑ, ¿¡Æ¿·» ºñ´Ò ¾Æ¼¼Å×ÀÌÆ®(EVA)Á¦ÀÇ ¼ö¾× ¹éÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¡¹æÀº ºñ ´Ù°ø¼º ±âÀç¿¡ ´ëÇÑ Á¢Âø·ÂÀÌ ¿ì¼öÇÏ¸ç °¡°Ýµµ Àú·ÅÇϱ⠶§¹®¿¡ ¼¼°è ¼öÁØÀÇ ÀÇ·á Àü¹®°¡¿¡°Ô ³Î¸® »ç¿ëµË´Ï´Ù. ½ÃÀå¿¡ ¹àÀº Àü¸ÁÀ» Á¦°øÇÏ´Â ±âŸ ¿äÀÎÀ¸·Î´Â »ý¹°ÇÐÀûÀ¸·Î ºÒȰ¼ºÀÎ ÀÇ·á¿ëǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ ´ëÆøÀûÀÎ °³Ã´, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°è ºñPVC IV¹é ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿äÀÎÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ Àç·áº° ³»¿ªÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ Á¦Ç°º° ³»¿ªÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ³»¿ªÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ºñPVC IV¹é ½ÃÀåÀÇ ÁÖ¿ä ÁøÃâ±â¾÷/±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°è ºñPVC IV¹é ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Àç·áº°

  • ¿¡Æ¿·» ºñ´Ò ¾Æ¼¼Å×ÀÌÆ®
  • °øÆú¸®¿¡½ºÅ׸£ ¿¡Å׸£
  • Æú¸®ÇÁ·ÎÇÊ·»
  • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • ¸ÖƼ è¹ö
  • ½Ì±Û è¹ö

Á¦8Àå ½ÃÀå ºÐ¼® : ³»¿ë¹°º°

  • ³Ãµ¿ È¥ÇÕ¹°
  • ¾×ü È¥ÇÕ¹°

Á¦9Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • È­Çпä¹ý
  • Ÿ°Ù ¾à¹°Àü´Þ
  • Æ÷µµ´ç ÁÖ»ç
  • ¿°È­³ªÆ®·ý ¿ë¾×
  • ÀüÇØÁú ÁÖÀÔ
  • ¿µ¾ç ÁÖÀÔ
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª: ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ±ä±Þ ¼­ºñ½º ¼¾ÅÍ
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦11Àå ½ÃÀå ºÐ¼®: Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦12Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °¡°Ý ºÐ¼®

Á¦16Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton Dickinson and Company
    • Fresenius SE & Co. KGaA
    • JW Life Science Co. Ltd.
    • Kraton Corporation(DL Chemical Co. Ltd.)
    • Medline Industries LP
    • Persico Spa
    • Sealed Air Corporation
    • Sippex IV bags
JHS 24.07.31

The global non-PVC IV bags market size reached US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032.

Non-polyvinyl chloride (non-PVC) intravenous (IV) bags are manufactured using polypropylene, polyethylene, copolyester-ether, and ethylene-vinyl acetate films. They are specifically designed for packaging rehydration solutions and storing certain antibiotics and analgesics for hospital and veterinary usage. Moreover, they can be extensively utilized in cold storage without inhibiting the quality and shelf-life of the stored items. Unlike PVC IV bags that often face drug and container interaction problems, these bags provide improved safety, lowered risks of contamination and enhanced convenience of usage. As a result, non-PVC IV bags find extensive applications in parenteral nutrition, oncology, chemotherapy, and targeted drug deliveries.

Non-PVC IV Bags Market Trends:

The market is primarily driven by the rising incidences of hospital-acquired infections (HAIs) among the masses. Coupled with the increasing influx of patients requiring intravenous antibiotics across healthcare facilities, this has provided a boost to the uptake of non-PVC IV bags. Also, the widespread adoption of single-chambered non-PVC IV bags in IV drips and other mixtures due to their convenience of management, transportation, and disposal is significantly contributing to the product sales. In addition to this, the growing number of point-of-care (POC) facilities across the globe and the preference for home care setups, especially for the geriatric population, are favorably impacting the market growth. The market is further driven by the escalating popularity of IV bags made up of ethylene-vinyl acetate (EVA). Since these bags offer excellent adhesion to non-porous substrates at an affordable price point, they are widely utilized by healthcare professionals on the global level. Some of the other factors creating a positive outlook for the market include the augmenting demand for biologically inert medical supplies, considerable developments in the healthcare infrastructure and extensive research and development (R&D) activities.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global non-PVC IV bags market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on material, product, content, application and end user.

Breakup by Material:

Ethylene Vinyl Acetate

Copolyester-ether

Polypropylene

Others

Breakup by Product:

Multi Chamber

Single Chamber

Breakup by Content:

Frozen Mixture

Liquid Mixture

Breakup by Application:

Chemotherapy

Targeted Drug Delivery

Glucose Injection

Sodium Chloride Solution

Electrolyte Injection

Nutrient Injection

Others

Breakup by End User:

Hospitals

Clinics

Emergency Service Centers

Ambulatory Surgical Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Fresenius SE & Co. KGaA, JW Life Science Co. Ltd., Kraton Corporation (DL Chemical Co. Ltd.), Medline Industries LP, Persico S.p.a., Sealed Air Corporation and Sippex IV bags.

Key Questions Answered in This Report

  • 1. What was the size of the global non-PVC IV bags market in 2023?
  • 2. What is the expected growth rate of the global non-PVC IV bags market during 2024-2032?
  • 3. What are the key factors driving the global non-PVC IV bags market?
  • 4. What has been the impact of COVID-19 on the global non-PVC IV bags market?
  • 5. What is the breakup of the global non-PVC IV bags market based on the material?
  • 6. What is the breakup of the global non-PVC IV bags market based on the product?
  • 7. What is the breakup of the global non-PVC IV bags market based on content?
  • 8. What is the breakup of the global non-PVC IV bags market based on the end user?
  • 9. What are the key regions in the global non-PVC IV bags market?
  • 10. Who are the key players/companies in the global non-PVC IV bags market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-PVC IV Bags Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Material

  • 6.1 Ethylene Vinyl Acetate
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Copolyester-ether
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Polypropylene
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Multi Chamber
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Single Chamber
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Content

  • 8.1 Frozen Mixture
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid Mixture
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Chemotherapy
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Targeted Drug Delivery
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Glucose Injection
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Sodium Chloride Solution
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Electrolyte Injection
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast
  • 9.6 Nutrient Injection
    • 9.6.1 Market Trends
    • 9.6.2 Market Forecast
  • 9.7 Others
    • 9.7.1 Market Trends
    • 9.7.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Emergency Service Centers
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Ambulatory Surgical Centers
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 B. Braun Melsungen AG
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 SWOT Analysis
    • 16.3.2 Baxter International Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Becton Dickinson and Company
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Fresenius SE & Co. KGaA
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 JW Life Science Co. Ltd.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Kraton Corporation (DL Chemical Co. Ltd.)
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Medline Industries LP
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Persico S.p.a.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
    • 16.3.9 Sealed Air Corporation
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sippex IV bags
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦